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Summary. Prematurity is a large problem worldwide. Premature infants are at high risk of developing chronic lung 
disease (CLD). Corticosteroids (CS) have been proven efficient in improving lung function and facilitating weaning of 
premature infants with CLD from mechanical ventilation. On the other hand, their use has been related to severe short- 
and long-term side effects. Over the years, CS have been widely used in many conditions in premature infants, but after 
a connection to severe side effects had been established, their use registered a large downfall, creating the perplexity 
whether to give CS or not. Clinicians may also be confused in deciding which synthetic CS to use and at what time, dose 
and duration. A difference in activity and side effects between dexamethasone (DEX) and hydrocortisone (HC) should 
thereby also be considered. This review describes acute and chronic side effects connected to CS and will attempt to shed 
light on how clinicians can minimize them.
Introduction
Corticosteroids (CS) have been introduced to perina-
tal medicine in 1972, when Liggins and Howie pub-
lished their discovery that prenatal betamethasone ad-
ministration reduces the incidence of respiratory dis-
tress syndrome (RDS)1. Postnatally, CS were used in 
newborns to facilitate weaning from ventilator and in 
the treatment of adrenal insufficiency and for arterial 
hypotension.
Nevertheless, recent reports have raised concerns that 
CS therapy during the perinatal period compromises 
growth and may cause permanent fetal neurodevelop-
mental impairment, as well as other acute and chronic 
complications.
In general, CS stimulates gluconeogenesis and glyco-
gen synthesis and release amino acids from muscles. 
Glucocorticoids drastically reduce signs of inflamma-
tion by modifying leukocyte activity as well as sup-
pressing cytokines, chemokines and other mediators of 
inflammation. Glucocorticoids inhibit the function of 
tissue macrophages and other antigen-presenting cells. 
The production of prostaglandins and leukotrienes is 
decreased by affecting the expression of cyclooxygen-
ase-22. After a single dose of a short-acting CS, the 
number of neutrophils increases, whereas the number of 
monocytes, eosinophils and basophils is decreased. The 
changes are most evident in the first 6 hours following 
administration and disappear completely after 24 hours.
Dexamethasone (DEX) has been the most commonly 
CS used in the prevention and treatment of chronic lung 
disease (CLD). DEX is a synthetic long-acting CS, with 
a half-life of 36–54 hours. The alternative is hydrocorti-
sone (HC), which is a short-to-medium-acting CS and is 
25–50 times less potent than DEX, with a half-life of 8 
hours. Some other synthetic CS used in perinatal medi-
cine are methylprednisolone and budesonide. This re-
view will focus more on intravenous rather than inhaled 
CS such as budesonide.
Prenatal administration of CS
Prenatal CS is administered with the aim to reduce 
the incidence of complications and morbidities con-
nected to preterm birth, such as RDS and CLD. Cortico-
steroids have been shown to have a considerable effect 
on intrauterine maturation, inducing both structural and 
functional changes of fetal organs. Structurally, CS in-
crease lung compliance by accelerating alveolarization, 
enhancing septal thinness and increasing pulmonary 
collagen and elastin growth. They also affect the fetal 
lungs by increasing the synthesis of both lipid and pro-
tein components of surfactant3. Effects of CS are not 
limited only to the fetal lungs; in the liver, CS increase 
the synthesis of a variety of proteins and growth factors. 
This is important in the transition period from fetus to 
newborn, to ensure the full number of nutritional re-
quirements at birth and in the immediate postnatal pe-
riod. In addition, CS increase the availability of adrena-
line after birth 4. It has been shown that infants receiv-
ing antenatal CS had a significantly lower mortality to 
discharge when compared to controls5. Corticosteroids 
are recommended for pregnant women from 23 to 33+6 
weeks who are at high risk of preterm delivery6. Four 
doses of DEX, of 6 mg for every 12 hours administered 
intramuscularly are recommended. A synthetic stereo-
isomer of DEX used for antenatal administration is be-
tamethasone, administered intramuscularly in a 12 mg 
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Betamethasone is favored for this indication due to its 
reduced attachment to maternal plasma proteins and 
less biodegradation in the placenta than other CS, there-
fore delivering a larger fraction of the dose to the fetus2.
Treatment with antenatal CS is connected to an over-
all reduction in newborn deaths, intraventricular hemor-
rhage, and necrotizing enterocolitis, as well as systemic 
infections6. These achievements described more than 45 
years ago, have led to widespread use of CS in perinatal 
medicine. From the early 1990s to 2012, antenatal CS 
usage increased from 24% to 87%7.
Side effects of CS used  
for prevention of RDS in infants
Despite the success in reducing morbidity and mor-
tality in preterm infants, several studies appeared with 
reports of adverse effects. One study has shown that 
there is a considerable transient reduction in fetal body 
and breathing movements and fetal heart rate variation 
after maternal betamethasone administration8. Howev-
er, it must also be noted that a return of these values to 
baseline levels was observed on day 4. A retrospective 
fear must therefore arise, of many unnecessarily in-
duced preterm births upon observation of the findings 
described above; then considered to be signs of fetal 
distress, but now suspected only to be a transient conse-
quence of prenatal CS administration. Furthermore, to 
evaluate the efficacy and safety of prenatally used CS, 
the dosage was also assessed. Even though data are 
scarce, many clinicians, to ensure that all newborns 
who are delivered preterm receive the optimal treat-
ment, often readminister CS when childbirth hasn’t oc-
curred in more than 7 days after the first dose. This 
study, which compared a single-dose application (one 
course of betamethasone 12 mg applied once in 24 
hours) versus weekly doses of antenatal CS (4 courses 
total, not including the qualifying course) concluded 
that repeated doses of antenatal CS reduce specific neo-
natal morbidities, but do not improve composite neona-
tal outcome. Composite neonatal outcomes in this study 
included RDS, intraventricular hemorrhage, periven-
tricular leukomalacia, CLD and stillbirth or neonatal 
death. Furthermore, this is followed by a reduction in 
birth weight of 95 grams and an increase in number of 
small for gestational age infants9. Even with these find-
ings in mind, there is still no consensus on how exactly 
to adjust the timing of CS administration and their dos-
age10. To conclude, there is a great amount of evidence 
that suggests that the use of prenatal steroids in preg-
nant women who are at risk of a preterm delivery re-
duces newborn mortality and complications. However, 
further studies on dosage and choice of prenatal steroids 
are needed.
Indications for CS  
in neonatal acute conditions
Corticosteroid treatment is indicated in newborns 
with congenital adrenal hyperplasia (CAH) and adrenal 
crisis, 20 to 30 mg/m2 of HC, divided three times per 
day. This is a life-saving treatment; therefore, these con-
ditions will not be mentioned in further text. Arterial hy-
potension is another condition in which CS may be con-
sidered. While not the first line of treatment, they should 
be considered when proper hydration and other drugs do 
not prove beneficial. In this case, HC is administered in 
a starting dose of 1–2 mg/kg every 12 hours. When an 
improvement in blood pressure and urine excretion is 
observed, the dose can be reduced to 0.5 mg/kg11.
Indications for CS  
in chronic neonatal conditions
Corticosteroids are indicated in prolonged mechani-
cal ventilation, with oxygen supplementation, and when 
there is a high risk of neonatal CLD. This condition of a 
very preterm infants is caused by persistent inflamma-
tion following preterm birth12. Well known anti-inflam-
matory properties of steroids including inhibition of 
prostaglandins, leukotrienes, and cyclooxygenase I and 
II, decreased neutrophil recruitment in the lungs, reduc-
tion of vascular permeability, and improvement of pul-
monary edema, make CS a logical solution for the treat-
ment of CLD. Moreover, CS has a very positive impact 
on the success of weaning of these patients from me-
chanical ventilation. These effects are achieved through 
several mechanisms: surfactant production enhance-
ment, antioxidant properties, bronchospasm decrease, 
reduction of pulmonary and bronchial edema, improve-
ment of vitamin A status and minimization of inflamma-
tory cells and mediator response13.
In such occasions the DART (Dexamethasone: A 
Randomized Trial) protocol can be used. The DART 
protocol prescribes the administration of intravenous 
DEX: 0.075 mg/kg per dose every 12 hours for three 
days, then 0.05 mg/kg per dose every 12 hours for three 
days, followed by 0.025 mg/kg per dose every 12 hours 
for two days, and lastly 0.01 mg/kg per dose every 12 
hours for two days14.
Corticosteroids usage in the 1990s rose from 29% in 
infants who survived more than 12 hours after birth, to 
41% in 1996, subsequently falling to 8% and remained 
relatively stagnant since. Even though postnatal CS us-
age declined, survival without major morbidity in-
creased 2% every year for newborns of a gestational age 
from 25 to 28 weeks7.
The explanation for such a drastic decrease in CS use 
can be found in several research papers which connect-
ed postnatal CS use with severe side effects, both acute 
and chronic. In Europe, a cohort study has recorded that 
13.9% of infants from 24 to 29 weeks of gestational age 
were treated with postnatal CS. Very extreme variations 
in CS usage between regions in Europe have been de-
scribed, ranging from 3.1% to 49.4% infants receiving 
CS for treatment of CLD15. A cohort study, 15-year ex-
perience treating extremely low birthweight infants in 
Australia, showed that even though CS usage fell in 
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2005 and was accompanied by the rise in CLD, there 
were no significant changes in mortality or neurological 
morbidity in comparison to earlier eras when CS were 
more widely used16.
Acute side effects
Postnatal CS treatment had been connected to many 
acute side effects. According to a Cochrane review by 
Doyle et al.17, an increased risk of gastrointestinal bleed-
ing and perforation was frequently described in studies 
focusing on early use of CS (less than 8 days of postna-
tal age), as well as hyperglycemia, hypertension, hyper-
trophic cardiomyopathy and growth failure. As for late 
administration CS, another Cochrane review revealed 
an increased risk of infection and gastrointestinal bleed-
ing, hyperglycemia, glycosuria and hypertension18. 
From this, we can conclude that short-term side effects 
can arise regardless of the time of the administration. A 
study conducted on 220 infants, randomly assigned into 
two groups – a placebo group and a DEX-treated group 
with doses of 0.15 mg/kg for 3 days, and then gradually 
tapered off during the next 7 days, showed that DEX-
treated patients were at an increased risk of developing 
hypertension, hyperglycemia and gastrointestinal perfo-
ration19. The latter occurred in 13% of treated patients, 
establishing itself in this study as a particularly danger-
ous acute CS side effect. Subsequently, its significance 
has been reaffirmed in other studies and case reports. 
These show an even greater increase of the risk of gas-
troduodenal perforation if DEX is given with indometh-
acin20,21. A lowered level of prostaglandins, which usu-
ally maintain the integrity of gastrointestinal mucosa, 
has been proposed as a possible cause of gastrointesti-
nal perforation associated with CS22. Decreased weight 
gain is also one of the side effects appearing in DEX-
treated patients23. A possible mechanism of growth fail-
ure may be related to a catabolic effect of CS, to which 
very low birth weight infants are more vulnerable. 
Therefore, in the earliest period of life, when infants 
naturally receive insufficient calories, their growth may 
be markedly affected24. Another side effect connected to 
DEX is hypertrophic cardiomyopathy. One study evalu-
ating the effects of early DEX on the heart studied a 
group of 20 patients receiving placebo and 20 patients 
who received 0.5 mg/kg DEX per day for 3 days, then 
0.25 mg/kg per day for 3 days, then 0.125 mg/kg per 
day for 7 days, started from fourth day of life, with car-
diac evaluations before, during and after the treatment 
with DEX. This study concluded, that DEX treatment 
relates to a significant increase in mean septal and left 
posterior wall thickness, as well as a decrease in mean 
left ventricle diameter. Twenty percent of infants devel-
oped left ventricular hypertrophy; however, complete 
resolution of hypertrophy was detected within the sec-
ond and third week following the discontinuation of 
DEX treatment25. Similar results were described in a 
case report – however, this time only a single dose of 
0.5 mg/kg was enough to cause the abovementioned 
phenomenon26. With evidence that DEX has a lot of 
acute side effects, HC was chosen as the drug of interest 
for other studies. A case report was published describ-
ing cardiac hypertrophy as a consequence of HC treat-
ment, with findings returning to normal after the treat-
ment was terminated27. However, it is obvious that 
larger studies are needed to confirm this side effect of 
HC. One study concluded, when comparing DEX- and 
HC-treated patients to their controls, that acute side ef-
fects such as hyperglycemia, high urea concentrations, 
hypertension, and impaired weight gain were connected 
only to DEX-treated patients in a dose of 0.5 mg/kg ta-
pering off to 0.1 mg/kg for 21 days and not to HC treat-
ment in a dose of 5 mg/kg tapering off to 1 mg/kg for 
total of 22 days28. One randomized clinical trial on a 
greater number of patients (379) showed that there was 
no significant difference between HC and controls in 
acute side effects such as hypertension, hyperglycemia, 
gastrointestinal perforation and necrotizing enterocoli-
tis. Only late-onset sepsis was found to be more fre-
quent in HC-treated infants from 24–25 weeks of life29. 
On the other hand, there are two studies which were 
interrupted because of high incidence of spontaneous 
gastrointestinal perforation, but neither showed a sig-
nificant increase in other acute side effects. In one of 
them, 25 patients received 2 mg/kg for 2 day, then 1.5 
mg/kg for 2 days, and 0.75 mg/kg for 6 days of HC. A 
total of 4 of 25 patients developed spontaneous gastro-
intestinal perforation, three of which received indo-
methacin or ibuprofen with HC30. In the other study, 
360 patients were divided into 2 groups, one placebo, 
and the other the HC group, receiving 1mg/kg per day 
for 12 days, then 0.5 mg/kg per day for 3 days. The re-
sults showed that HC-treated patients who received in-
domethacin had a higher risk of gastrointestinal perfo-
ration than the placebo group also receiving indometha-
cin, whereas the risk was non-significant when compar-
ing HC-treated infants without indomethacin with 
controls, also without indomethacin31. The studies sug-
gest that combining CS with indomethacin or ibuprofen 
should be abandoned because of a high risk of gastroin-
testinal perforation in preterm infants. To conclude, HC 
in a low dose is not associated with acute side effects, 
and the elevated risk of gastrointestinal perforation is 
lowered if indomethacin or ibuprofen are omitted.
Chronic side effects of CS used  
for the treatment of neonatal conditions
Chronic side effects have been the main reason for 
the decline in postnatal CS use almost all around the 
world. The main reason for this decrease is the influx of 
reports connecting postnatal CS usage to neurodevelop-
mental side effects such as cerebral palsy (CP). A study 
on rodents suggested that CS may be the reason for de-
layed dendritic cortical branching32. A follow-up to a 
randomized, double blinded, placebo-controlled study 
published in 2000, concluded that DEX was associated 
with a significant increase in frequency of CP and neu-
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rodevelopmental delay33. This follow-up included 80 
patients which received 0.25 mg/kg DEX every 12 
hours for a total of 6 doses in the first three days of life 
for the prevention of CLD and 79 placebo-treated pa-
tients. They were assessed at a mean age of 53 months 
(range from 24 to 71). DEX-treated patients had a sig-
nificantly higher incidence of CP (49%) than placebo-
treated patients (15%) and developmental delay was 
also more common in the DEX group (55% vs. 29%). 
This study raised considerable alarm regarding DEX 
use in preterm infants, and an urgent need for further 
studies to determine the dose and timing of CS became 
apparent. On the other hand, it is known that patients 
with CLD, as a whole, have a lower average IQ, they 
have more academic difficulties, behavioral problems 
and delayed speech and language development at school 
age34. This may suggest that neurodevelopmental diffi-
culties may not be exclusively connected to postnatal 
CS administration but are also associated to CLD itself. 
In 2000 Doyle et al35 performed a meta-analysis of 27 
randomized clinical trials studying the effects of CS on 
mortality and motor function. They concluded that the 
overall mortality rate was not significantly higher but 
found that the rate of motor dysfunction was indeed sig-
nificantly higher in the CS group. One of the studies 
included in the meta-analysis was conducted on neo-
nates using an early treatment (at less than 4 days post-
natal), while four studies considered neonates who were 
treated later (at more than 14 days postnatal). When ex-
cluding the study with early treatment, the rate of motor 
dysfunction was not statistically significantly higher in 
the CS group (23% vs. 15%). On the contrary, other 
three studies showed that CS treatment, even started 
later, is related to significantly higher rates of CP (22.9% 
vs. 14.2%). This meta-analysis raised a lot of questions 
concerning the time of CS treatment, and furthermore 
showed that CS do not reduce mortality. One study, 
where 30 neonates, who were oxygen and ventilator de-
pendent on 10th day of life with a high risk of CLD, 
were divided into 2 groups, with 15 neonates treated 
with DEX with a total dose of 0.5/mg/kg/day for six 
days, 0.25/mg/kg/day for another six days, and 0.125 
mg/kg/day for two days with a total dose of 4.75 mg/kg 
over 14 days from the 10th day of life and 15 untreated, 
were followed up at 36–42 months adjusted postnatal 
age. In regards to this dose and timing of DEX adminis-
tration, no significant difference was found in mean 
body weight and head circumference, as well as the in-
cidence of CP, major neurosensory impairment, mean 
IQ scores or behavioral abnormalities in neonates at 
three-year follow up36. In 2001 another meta-analysis 
was performed on 8 randomized control trials that in-
cluded at least some report of a long-term neurodevel-
opmental outcome in infants treated with CS for pre-
vention of CLD. These studies were divided into 2 
groups regarding the extent of result contamination, 
defined as CS treatment of controls after the study pe-
riod. This meta-analysis concluded that the relative risk 
of CP in a group with less than 30% result contamina-
tion was 2.86 and the relative risk for neurodevelop-
mental disability was 1.66, stating that, without any 
evidence of long-term benefits, CS should not be used 
for this indication37. Eventually, as a result of collected 
evidence over the years, American Academy of Pediat-
rics indeed recommended that routine use of systemic 
DEX for prevention or treatment of CLD should be 
abandoned and called for further trials investigating the 
use of alternative CS, systemic or inhaled12. On the one 
hand, there is evidence that DEX facilitates early extu-
bation and weaning from mechanical ventilation in pre-
term infants, and it has been proven that low doses (0.89 
mg/kg) are also effective over 10 days14. On the other 
hand, a strong connection exists between DEX and CP, 
especially when DEX is given in high doses during ear-
ly days of life. Doyle et al38 set an objective to assess the 
modification of the effect of CS on CP and mortality, 
when risk of CLD is taken into account. After 20 ran-
domized control trials had been studied, the authors 
concluded that if the risk for CLD was below 35%, ad-
ministration of CS was connected to a significant in-
crease in chance of death or CP. On the other hand, 
when this risk exceeds 65%, then the chance is de-
creased. They also reported an increase in CP in early 
CS therapy, but not in late-administered CS. Neverthe-
less, even in late use of CS, overall benefits could not be 
proven. It can be concluded that only patients at a high 
risk of CLD should receive CS, at the appropriate time 
and dose, to ensure that the benefit surpasses the risks. 
In 2009, a nested study was conducted inside a prospec-
tive trial on 1667 extremely low birth weight survivors 
treated late (at more than 7 days postnatal) with CS 
(94% DEX) and examined at 18–22 months of post-
menstrual age. A total of 72% of patients treated with 
CS were at high risk for CLD. The study concluded that 
the rise in neurodevelopmental impairment correlated 
with an increase in dose of CS, where 71% receiving the 
highest dose achieved a fatal outcome or impairment. 
For every 1 mg/kg of CS, a 2-point decrease of the men-
tal development index and a 40% increase in risk of CP 
was remarked. In regards of treatment timing, treating 
infants at 33 weeks of postmenstrual age was associated 
with the greatest harm39. As was the case with Doyle et 
al38, this nested study observed that infants with the 
highest risk of developing CLD had fewer harmful out-
comes. A recent study from 2017 studied 412 infants of 
a gestational age of 23–28 weeks who were on mechan-
ical ventilation, 29% of which having received DEX 
(mean cumulative dose was 7.8 mg/kg). The outcomes 
of interest were respiratory-related hospital admissions 
in the past 12 months and neurodevelopmental impair-
ment. It was concluded that both early and late DEX 
groups show a significantly higher frequency of respira-
tory readmissions (0.35 vs 0.15), a higher incidence of 
neurodevelopmental impairment, hearing, vision, com-
munication or other disabilities, as well as CP (0.59 vs 
0.45)40. A Cochrane review of studies on late (after 7 
days postnatal) CS treatment, performed in 2017, found 
no significant difference between CS treatment and 
controls regarding the combined rate of death, CP, or 
neurosensory disability. The authors recommended that 
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late CS therapy should be reserved for neonates who 
cannot be weaned from mechanical ventilation18. An-
other Cochrane review in 2017 examined studies of 
early systemic CS therapy (at less than 8 days) for the 
prevention of CLD and found an increased risk of ab-
normal findings on neurological examination and an 
increased risk of CP in these patients. However, the au-
thors also warned that no study had been conducted af-
ter the school age or had neurodevelopmental impair-
ment as a primary outcome. Hydrocortisone as well as 
DEX showed a reduction in rates of patent ductus arte-
riosus, mortality or CLD, but without evidence of long-
term harm17. This stressed a greater need for HC trials, 
as it may be better than DEX for this indication.
Hydrocortisone, to be considered as a possible re-
placement for DEX, should be as efficient in facilitating 
weaning from mechanical ventilation and have less side 
effects. A retrospective study conducted in 2003 inves-
tigated the short and long-term benefits of both HC and 
DEX in two centers. All patients received CS because 
of impossibility of weaning from the ventilator and had 
a high risk for CLD. This study showed that HC and 
DEX are equally potent in reducing oxygen dependen-
cy. Most importantly, on late follow-up at 5 to 7 years of 
age, the group of DEX-treated patients had a signifi-
cantly increased number of neurodevelopmental dis-
abilities, and more than 50% of them needed special 
school education. HC-treated patients, on the other 
hand, showed no difference in neurodevelopmental out-
comes in comparison to controls28. Another late follow-
up study conducted at 8 years of age used magnetic 
resonance imaging (MRI) and Wechsler Intelligence 
Scales for Children- Revised (WISC-R) neurocognitive 
assessments. A reduced volume of grey matter (649 mL 
vs. 666mL) was found in preterm infants, as well as an 
increased volume of cerebrospinal fluid (228 mL vs. 
206 mL). Total hippocampal volume was decreased 
(6.1 mL vs. 6.56 mL) and WISC-R score lowered for 
preterm children (99.4 vs. 109). When comparing HC-
treated preterm children to preterm children without HC 
therapy, there was no significant difference between the 
two groups in any of the categories mentioned above41. 
There has been a number of other studies which seem to 
give support to the claim that treatment with HC shows 
no long term side effects42,43. Despite these findings, it 
was considered that a larger study was required. One 
such study, conducted in 2007 on a larger number of 
patients, seemed to confirm previously listed conclu-
sions. A total of 62 patients were treated for CLD with 5 
mg/kg/day of HC. This group was compared to 163 
controls. Similarly to the studies discussed above, these 
patients were followed up at 7–8 years old, and again 
the group that underwent HC treatment showed no sig-
nificant difference in comparison to controls in regards 
to motor function (Movement Assessment Battery for 
Children) and the incidence of CP as well44. A Cochrane 
review recognized the potential of HC in reducing the 
outcomes of mortality and/or CLD without any long-
term harm17. Gupta et al45 concluded in a 2011 that none 
of the included multicentered RCTs or cohort studies 
revealed any side effects of neonatal HC treatment on 
functional or structural neurological outcomes. One ret-
rospective cohort study from 2014 was conducted on 
175 extremely low birth weight infants. A total of 86 of 
them received a maximum daily dose of 3 mg/kg HC 
per day. The attending physician documented the indi-
cation for HC treatment, which were divided according 
to indication into infants treated with HC for hypoten-
sion, respiratory status or other. These infants were neu-
rologically examined at both 8 months and 20 months 
of corrected age and compared to 89 controls. At 8 
months, HC-treated patients were shown to have lower 
mean motor and fine motor scores. Additionally, the cu-
mulative duration of HC therapy was deemed a nega-
tive predictor of language outcomes at 8 months follow-
up, as well as of motor outcomes at 20 months46. How-
ever, on second follow-up at 20 months, language and 
fine motor skills were observed as having improved. 
This study warned about the effect of cumulative days 
of HC exposure on extremely low birth weight infants. 
Although a lower dose than in other studies was used, it 
was the duration of HC treatment that was connected to 
motor abnormalities at 20 months of age. This is not the 
only study showing neurodevelopmental abnormalities 
in connection to HC therapy. An example is a follow-up 
study on a randomized trial of early neonatal HC treat-
ment published in 2016, with the aim of evaluating neu-
rodevelopment and growth of 5 to 7-year-old children 
treated with HC in the first days since premature birth. 
All the patients in this study were on mechanical venti-
lation in the first day of life. This original study was 
however terminated, because of increased risk for gas-
trointestinal perforation in the HC group. Eighty per-
cent of children continued to participate in the study at 
the 5 to 7-year mark. The conclusion in this instance 
was that neurodevelopmental impairment occurred in a 
significantly larger percentage within the HC group 
(61% vs. 39%). HC-treated patients had a lowered mean 
full-scale IQ (87.8 vs. 95.7) and mean performance IQ 
(88.3 vs. 99.1); 22% of HC-treated patients had a need 
for physiotherapy (22% vs 0%) and the need for speech 
therapy was higher in HC group as well (47% vs. 
28%)47. These studies indicate that HC should not be 
used in the first days of life, and not in a longer duration 
than 40 days. There is a noticeable need for similar 
studies that aim to pinpoint the ideal duration and tim-
ing of HC treatment, but on a larger number of patients. 
In 2016, for example, a multicenter randomized trial 
was conducted on extremely preterm infants (<28 
weeks of gestation) to assess if low-dose HC therapy 
improves survival without CLD. Infants were assigned 
into 2 groups, 266 of which received placebo and 255 
infants received 1 mg/kg of HC per day. It was shown 
that HC significantly improved survival without CLD at 
36 weeks of age. Furthermore, HC significantly in-
creased the proportion of extubated infants at the end of 
the study, reduced the need for surgical ligation of pat-
ent ductus arteriosus, and increased the percentage of 
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infants who do not need supplemental oxygen at 36 
weeks29. This study used the lowest dose that has so far 
been proven to increase survival of CLD. Even though 
HC had been administered from the first day of life, a 
follow-up study at 2 years of age showed no significant 
difference in neurodevelopmental impairment48. To sum 
up, so far HC has proved to be as efficient as DEX with 
less short-term and long-term side effects. A lower dose 
and shorter duration of HC therapy is generally re-
commended, but future studies are needed to identify 
the exact dose and duration, so that clinicians can uti- 
lize this treatment without fear of acute or chronic side 
effects.
Conclusion
Postnatal CS treatment of preterm infants is helpful 
in terms of weaning from mechanical ventilation and 
improving lung function. However, these beneficial ef-
fects are accompanied by significant acute and chronic 
side effects. Clinicians need to outweigh the ratio of risk 
and benefit for each individual infant they treat, keeping 
in mind that only infants at high risk of CLD are likely 
to benefit from this treatment. Early administration of 
DEX should be avoided, while HC arises as a more 
comfortable choice with less short- and long-term side 
effects, especially in a low dose. Further studies to de-
termine the appropriate dosage and correct timing of CS 
may give more insight in the question of postnatal CS 
treatment in the future.
References
1. Liggins GC, Howie RN. A controlled trial of antepartum 
glucocorticoid treatment for prevention of the respiratory dis-
tress syndrome in premature infants. Pediatrics. 1972;50(4).
2. Katzung BG, Masters SB, Trevor AJ. Basic & CLinical 
Pharmacology, Eleventh Edition. McGraw-Hill Companies, Inc; 
2009.
3. Warburton D, Parton L, Buckley S, Cosico L, Enns G, 
Saluna T. Combined effects of corticosteroid, thyroid hormones, 
and (β-agonist on surfactant, pulmonary mechanics, and 
β-receptor binding in fetal lamb lung. Pediatr Res. 1988;24(2): 
166–170.
4. Fowden AL, Li J, Forhead AJ. Glucocorticoids and the 
preparation for life after birth: are there long-term consequences 
of the life insurance? Proc Nutr Soc. 1998;57:113–122.
5. Travers CP, Clark RH, Spitzer AR, Das A, Garite TJ, Carlo 
WA. Exposure to any antenatal corticosteroids and outcomes in 
preterm infants by gestational age : prospective cohort study. Br 
Med J. 2017;356:j1039. doi:http://dx.doi.org/10.1136/bmj.j1039
6. Roberts D, Dalziel SR. Antenatal corticosteroids for accel-
erating fetal lung maturation for women at risk of preterm birth. 
In: Roberts D, ed. Cochrane Database of Systematic Reviews. 
Vol 42. Chichester, UK: John Wiley & Sons, Ltd; 2006:1443–
1447. doi:10.1002/14651858.CD004454.pub2
7. Stoll BJ, Hansen NI, Bell EF, et al. Trends in Care Prac-
tices, Morbidity, and Mortality of Extremely Preterm Neona- 
tes, 1993–2012. JAMA. 2015;314(10):1039. doi:10.1001/
jama.2015.10244
8. Derks JB, Zonneveld MF, Bruinse HW, Visser GHA. Tran-
sient reduction in fetal activity and heart rate variation after ma-
ternal betamethasone administration. Early Hum Dev. 1994; 
36:49–60.
9. Wapner RJ, Sorokin Y, Thom EA, et al. Single versus 
weekly courses of antenatal corticosteroids: Evaluation of safety 
and efficacy. Am J Obstet Gynecol. 2006;195(3):633–642. doi: 
10.1016/j.ajog.2006.03.087
10. Kemp MW, Newnham JP, Challis JG, Jobe AH, Stock SJ. 
The clinical use of corticosteroids in pregnancy. Hum Reprod 
Update. 2015;0(0):1–20. doi:10.1093/humupd/dmv047
11. Johnson PJ. Hydrocortisone for Treatment of Hypoten-
sion in the Newborn. Neonatal Netw. 2015;34(1):46–51. doi: 
10.1891/0730-0832.34.1.46
12. Committee on Fetus and Newborn. Postnatal Corticoste-
roids to Treat or Prevent Chronic Lung Disease in Preterm 
Infants. Pediatrics. 2002;109(2):330–338. doi: 10.1542/peds. 
109.2.330
13. Bancalari EM, Polin RAM. The Newborn Lung Neona-
tology Questions and Controversies, Second Edition. Saunders, 
an imprint of Elsevier, Inc.; 2012.
14. Doyle LW. Low-Dose Dexamethasone Facilitates Extu-
bation Among Chronically Ventilator-Dependent Infants: A 
Multicenter, International, Randomized, Controlled Trial. Pedi-
atrics. 2006;117(1):75–83. doi:10.1542/peds.2004-2843
15. Nuytten A, Behal H, Duhamel A, et al. Evidence-Based 
Neonatal Unit Practices and Determinants of Postnatal Cortico-
steroid-Use in Preterm Births below 30 Weeks GA in Europe. A 
Population-Based Cohort Study. Simeoni U, ed. PLoS One. 
2017;12(1):e0170234. doi:10.1371/journal.pone.0170234
16. Cheong JL, Anderson P, Roberts G, Duff J, Doyle LW. 
Postnatal corticosteroids and neurodevelopmental outcomes in 
extremely low birthweight or extremely preterm infants: 15-year 
experience in Victoria, Australia. Arch Dis Child – Fetal Neona-
tal Ed. 2013;98(1):F32-F36. doi:10.1136/fetalneonatal- 
2011-301355
17. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. 
Early (< 8 days) systemic postnatal corticosteroids for preven-
tion of bronchopulmonary dysplasia in preterm infants. Co-
chrane Database Syst Rev. 2017;2017(10). doi:10.1002/14651 
858.CD001146.pub5
18. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. 
Late (> 7 days) systemic postnatal corticosteroids for prevention 
of bronchopulmonary dysplasia in preterm infants. Cochrane 
Database Syst Rev. 2017;(10). doi:10.1002/14651858.CD0011 
45.pub4
19. Stark AR, Waldemar CA, Tyson JE, Papile, Lu-Ann 
MPH. Adverse effects of early dexamethasone treatment in ex-
tremely-low-birth-weight infants. N Engl J Med. 2001;344(2): 
95–101.
20. Ng PC, Brownlee KG, Dear PR. Gastroduodenal perfora-
tion in preterm babies treated with dexamethasone for broncho-
pulmonary dysplasia. Arch Dis Child. 1991;66:1164–1166.
21. Jobe AH. Postnatal Corticosteroids for Bronchopul-
monary Dysplasia. Clin Perinatol. 2009;36(1):177–188. doi: 
10.1016/j.clp.2008.09.016
22. Goodman LS, Gilman A. Goodman & Gilman’s The Phar-
macological Basis of Therapeutics. 9th ed. (Hardman J, Limbird 
L, eds.). New York: McGraw-Hill Companies, Inc; 1996.
23. Halliday H, Ehrenkranz R, Doyle L. Early postnatal (<96 
hours) corticosteroids for preventing chronic lung disease in 
 preterm infants. In: Halliday H, ed. The Cochrane Database of 
27
Gynaecol Perinatol 2018;27(1–2):21–28 Juroš F. et al. Acute and chronic side effects of corticosteroids used for treatment of neonatal conditions
Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 
2003. doi:10.1002/14651858.CD001146
24. Tsai FJ, Tsai CH, Wu SF, Liu YH, Yeh TF. Catabolic ef-
fect in premature infants with early dexamethasone treatment. 
Acta Paediatr. 1996;85(12):1487–1490. doi: 10.1111/j.1651- 
2227.1996.tb13957.x
25. Zecca E, Papacci P, Maggio L, et al. Cardiac Adverse 
 Effects of Early Dexamethasone Treatment in Preterm Infants : 
A Randomized Clinical Trial. J Clin Pharmacol. 2001;41: 
1075–1081.
26. Kale Y, Aydemir O, Ceylan O, Bas AY, Demirel N. Hy-
pertrophic Cardiomyopathy After a Single Dose of Dexametha-
sone in a Preterm Infant. Pediatr Neonatol. 2015;56(4):268–270. 
doi:10.1016/j.pedneo.2013.03.015
27. Vimala J, Prabhu A, Pavithran S, Kumar RNS. Hydrocor-
tisone induced hypertrophic cardiomyopathy. Int J Cardiol. 
2011;150(3):e94-e95. doi:10.1016/j.ijcard.2009.12.012
28. Heide-Jalving M van der, PJGH K, Laan M van der, et al. 
Short- and long-term effects of neonatal glucocorticoid therapy: 
is hydrocortisone an alternative to dexamethasone? Acta Paedi-
atr. 2003;92(7):827–835. doi:10.1080/08035250310002425
29. Baud O, Maury L, Lebail F, et al. Effect of early low-dose 
hydrocortisone on survival without bronchopulmonary dys-
plasia in extremely preterm infants (PREMILOC): a double- 
-blind, placebo-controlled, multicentre, randomised trial. Lan-
cet. 2016;387(10030):1827–1836. doi:10.1016/S0140-6736(16) 
00202-6
30. Peltoniemi O, Kari MA, Heinonen K, et al. Pretreatment 
cortisol values may predict responses to hydrocortisone admin-
istration for the prevention of bronchopulmonary dysplasia in 
high-risk infants. J Pediatr. 2005;146(5):632–637. doi:10.1016/j.
jpeds.2004.12.040
31. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of 
Early Adrenal Insufficiency to Prevent Bronchopulmonary Dys-
plasia: A Multicenter Trial. Pediatrics. 2004;114(6):1649–1657. 
doi: 10.1542/peds.2004-1159
32. Schapiro S. Some physiological, biochemical, and behav-
ioral consequences of neonatal hormone administration: Corti-
sol and thyroxine. Gen Comp Endocrinol. 1968;10(2):214–228. 
doi: 10.1016/0016-6480(68)90028-2
33. Shinwell ES, Karplus M, Reich D, et al. Early postnatal 
dexamethasone treatment and increased incidence of cerebral 
palsy. Arch Dis Child – Fetal Neonatal Ed. 2000;83:F177–F181.
34. Marlow N, Wolke D, Bracewell MA, Samara M. Neuro-
logic and Developmental Disability at Six Years of Age after 
Extremely Preterm Birth. N Engl J Med. 2005;352(1):9–19. doi: 
10.1056/NEJMoa041367
35. Doyle LW, Davis PG. Review Article Postnatal cortico-
steroids in preterm infants : Systematic review of effects on 
mortality and motor function. J Paediatr Child Health. 2000; 
36:101–107.
36. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo 
G. A three year follow up of preterm infants after moderately 
early treatment with dexamethasone. Arch Dis Child Fetal Neo-
natal Ed. 2002;87:F55–F58.
37. Barrington KJ. The adverse neuro-developmental effects 
of postnatal steroids in the preterm infant : a systematic review 
of RCTs. BMC Pediatr. 2001;1(1).
38. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sin-
clair JC. Impact of Postnatal Systemic Corticosteroids on Mor-
tality and Cerebral Palsy in Preterm Infants: Effect Modification 
by Risk for Chronic Lung Disease. Pediatrics. 2005;115:655. 
doi:10.1542/peds.2004-1238
39. Wilson-Costello D, Walsh MC, Langer JC, et al. Impact 
of Postnatal Corticosteroid Use on Neurodevelopment at 18 
to 22 Months’ Adjusted Age: Effects of Dose, Timing, and 
Risk of Bronchopulmonary Dysplasia in Extremely Low Birth 
Weight Infants. Pediatrics. 2009;123(3):e430-e437. doi:10.1542/
peds.2008-1928
40. Qin G, Lo JW, Marlow N, Calvert SA, Greenough A, Pea-
cock JL. Postnatal dexamethasone, respiratory and neurodevel-
opmental outcomes at two years in babies born extremely pre-
term. Morty RE, ed. PLoS One. 2017;12(7). doi:10.1371/jour-
nal.pone.0181176
41. Lodygensky GA. Structural and Functional Brain De-
velopment After Hydrocortisone Treatment for Neonatal Chron-
ic Lung Disease. Pediatrics. 2005;116:1. doi:10.1542/peds. 
2004-1275
42. Parikh NA, Kennedy KA, Lasky RE, McDavid GE, Ty-
son JE. Pilot Randomized Trial of Hydrocortisone in Ventilator-
Dependent Extremely Preterm Infants: Effects on Regional 
Brain Volumes. J Pediatr. 2013;162(4):685–690.e1. doi: 
10.1016/j.jpeds.2012.09.054
43. Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth 
and Neurodevelopmental Outcomes After Early Low-Dose Hy-
drocortisone Treatment in Extremely Low Birth Weight Infants. 
Pediatrics. 2007;120(1):40–48. doi:10.1542/peds.2006-3158
44. Rademaker KJ, Uiterwaal CSPM, Groenendaal F, Uniken 
Venema MMAT. Neonatal Hydrocortisone Treatment: Neurode-
velopmental Outcome and MRI at School Age in Preterm-born 
Children. J Pediatr. 2007;150:351–357.
45. Gupta S, Prasanth K, Chen C, Yeh TF. Postnatal Cortico-
steroids for Prevention and Treatment of Chronic Lung Disease 
in the Preterm Newborn. Int J Pediatr. 2012;2012:1–12. doi: 
10.1155/2012/315642
46. Patra K, Greene MM, Silvestri JM. Neurodevelopmental 
impact of hydrocortisone exposure in extremely low birth 
weight infants: outcomes at 1 and 2 years. J Perinatol. 2015; 
35(1):77–81. doi:10.1038/jp.2014.133
47. Peltoniemi OM, Lano A, Yliherva A, Kari MA, Hallman 
M. Randomised trial of early neonatal hydrocortisone demon-
strates potential undesired effects on neurodevelopment at pre-
school age. Acta Paediatr. 2016;105(2):159–164. doi:10.1111/
apa.13074
48. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Al-
berti C. Association Between Early Low-Dose Hydrocortisone 
Therapy in Extremely Preterm Neonates and Neurodevelopmen-
tal Outcomes at 2 Years of Age. JAMA. 2017;317(13):1329. 
doi:10.1001/jama.2017.2692
Address for correspondence: Prof. Boris Filipović-Grčić M.D., 
Ph.D., School of Medicine University of Zagreb, Department 
of Pediatric, UHC Zagreb, Mije Kišpatića 12, 10 000 Zagreb, 
Republic of Croatia; e-mail: borisfilipovicgrcic@gmail.com
Paper received: February 13th, 2019; paper accepted: March 
27th, 2019.
28
Gynaecol Perinatol 2018;27(1–2):21–28 Juroš F. et al. Acute and chronic side effects of corticosteroids used for treatment of neonatal conditions
1Medicinski fakultet Sveučilišta u Zagrebu;  
2Zavod za endokrinologiju, dijabetes i bolesti metabolizma “Mladen Sekso”, KBC “Sestre Milosrdnice Zagreb;  
3Zavod za neonatologiju i neonatalnu intenzivnu medicinu, Klinika za pedijatriju, KBC Zagreb
AKUTNE I KRONIČNE NUSPOJAVE KORTIKOSTEROIDA  
U LIJEČENJU NOVOROĐENČADI
1Filip Juroš, 2Maja Filipović-Grčić, 1,3Boris Filipović-Grčić
Pregledni članak
Ključne riječi: deksametazon, hidrokortizon, neurorazvoj, novorođenče, nuspojave
Sažetak. Prerano rođena novorođenčad i komplikacije koje se pojavljuju kod njih problem su u cijelome svijetu. Takva 
djeca su pod velikim rizikom razvijanja kronične plućne bolesti (CLD). S obzirom na upalnu etiologiju CLD-a, kortiko-
steroidi (CS) su predstavljeni kao logičan izbor liječenja takvog stanja. Oni su se pokazali vrlo učinkovitima u po-
pravljanju plućne funkcije i u ubrzavanju odvajanja djece sa respiratora. Prvi CS korišten za ovu indikaciju je bio 
deksametazon (DEX) koji se od 1990-tih sve više koristi, do 41% u postnatalno vrijeme, da bi se do danas smanjio na 
8%. Razlog tom drastičnom padu uporabe CS-a leži upravo u povezanosti sa akutnim i kroničnim nuspojavama. Uz 
akutne nuspojave, otkrilo se da CS-i mogu biti povezani s cerebralnom paralizom (CP) u nedonoščadi. S obzirom na to, 
savjetuje se da se DEX koristi u situacijama kada je novorođenče i nakon 2 do 3 tjedna i dalje mehanički ventilirano i 
kada postoji izraziti rizik od razvoja CLD-a, i to u što manjoj dozi. Hidrokortizon (HC) je još jedan sintetski CS, koji 
svojim mogućnostima odgovara kortizolu, istraživan je kao moguća zamjena DEX-u. Dokazi su pokazali da HC ima 
jednako dobar učinak u novorođenčadi u prevenciji CLD-a i u odvajanju od mehaničke ventilacije kao i DEX. Hidrokor-
tizon nije bio značajno povezan s akutnim nuspojavama kao DEX, osim s povećanom učestalošću spontane intestinalne 
perforacije u kombinaciji s indometacinom ili ibuprofenom. U studijama koje su pratile djecu tretiranu HC-om kroz 7–8 
godina, HC nije bio statistički povezan sa većom učestalošću neuroloških nuspojava ni CP-e. Samo je par studija uočilo 
neurorazvojne probleme uz liječenje HC-om, no te studije su ili koristile HC rano nakon rođenja u većim dozama ili 
tijekom dužeg razdoblja (>37 dana). Zaključno, postnatalni CS su korisni u odvajanju od respiratora i u poboljšanju 
plućne funkcije u nedonoščadi. Međutim, ovi dobri učinci su popraćeni akutnim i kroničnim nuspojavama. Kliničari bi 
trebali za svakog pojedinog pacijenta odvagnuti koristi i rizike, tako da samo ona novorođenčad koja imaju veliki rizik 
za razvoj CLD-a budu liječeni CS-ma.
